This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miederer, M. Articles by Scheinberg, D. A. Search for Related Content PubMed PubMed Citation Articles by Miederer, M. Articles by Scheinberg, D. A.

Treatment of Neuroblastoma Meningeal Carcinomatosis with Intrathecal Application of -Emitting Atomic Nanogenerators Targeting Disialo-Ganglioside GD2

Departments of ¹ Molecular Pharmacology and Chemistry and ² Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York; and ³ Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania

Labeling of specific antibodies with bifunctional chelated Actinium-225 (²²⁵Ac; an generator) allows the formation of new, highly potent and selective -emitting anticancer drugs. We synthesized and evaluated a radioimmunoconjugate based on 3F8, an IgG₃ antibody that specifically binds to ganglioside GD2, which is overexpressed by many neuroectodermal tumors including neuroblastoma. The ²²⁵Ac-1,4,7,10-tetra-azacylododecane (DOTA)-3F8 construct was evaluated for radiochemical purity and sterility, immunoreactivity, cytotoxicity in vitro, induction of apoptosis on GD2-positive cells, as well as for pharmacological biodistribution and metabolism of the ²²⁵Ac generator and its daughters in a nude mouse xenograft model of neuroblastoma. The ²²⁵Ac-3F8 showed an IC₅₀ of 3 Bq/ml (80 pCi/ml) on the neuroblastoma cell line, NMB7, in vitro. Apoptosis of these cells was not observed. Biodistribution in mice showed specific targeting of a subcutaneous tumor; there was redistribution of the ²²⁵Ac daughter nuclides mainly from blood to kidneys and to small intestine. Toxicity was examined in cynomolgus monkeys. Monkeys injected with 1 to 3 doses of intrathecal ²²⁵Ac-3F8 radioimmunoconjugate (80 to 150 kBq/kg total dose) did not show signs of toxicity based on blood chemistry, complete blood counts, or by clinical evaluations. Therapeutic efficacy of intrathecal ²²⁵Ac-3F8 was studied in a nude rat xenograft model of meningeal carcinomatosis. The ²²⁵Ac-3F8 treatment improved survival 2-fold from 16 to 34 days (P = 0.01). In conclusion, in vivo generators targeted by 3F8 warrant additional study as a possible new approach to the treatment of carcinomatous meningitis.

This article has been cited by other articles:

				K. Kramer, J. L. Humm, M. M. Souweidane, P. B. Zanzonico, I. J. Dunkel, W. L. Gerald, Y. Khakoo, S. D. Yeh, H. W. Yeung, R. D. Finn, et al. Phase I Study of Targeted Radioimmunotherapy for Leptomeningeal Cancers Using Intra-Ommaya 131-I-3F8 J. Clin. Oncol., December 1, 2007; 25(34): 5465 - 5470. [Abstract] [Full Text] [PDF]

				J. Dahle, J. Borrebaek, T. J. Jonasdottir, A. K. Hjelmerud, K. B. Melhus, O. S. Bruland, O. W. Press, and R. H. Larsen Targeted cancer therapy with a novel low-dose rate {alpha}-emitting radioimmunoconjugate Blood, September 15, 2007; 110(6): 2049 - 2056. [Abstract] [Full Text] [PDF]

				J. S. Jaggi, S. V. Seshan, M. R. McDevitt, K. LaPerle, G. Sgouros, and D. A. Scheinberg Renal Tubulointerstitial Changes after Internal Irradiation with {alpha}-Particle-Emitting Actinium Daughters J. Am. Soc. Nephrol., September 1, 2005; 16(9): 2677 - 2689. [Abstract] [Full Text] [PDF]